Arrowstreet Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Arrowstreet Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$897K	Buy	+421,178	New	+$724K	﹤0.01%	1658

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Arrowstreet Capital's ALDX Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Aldeyra Therapeutics (ALDX) in Q2 2026: 421,178 shares worth $897K. The stake represents ﹤0.01% of the portfolio and ranks #1658 among its holdings.

108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Arrowstreet Capital held 421,178 shares of Aldeyra Therapeutics worth $897K as of Q2 2026.
Aldeyra Therapeutics was a new Arrowstreet Capital position in Q2 2026.
Aldeyra Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1658 holding.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.